Key result
Bailout GPIs for PCI complications are linked to ~465% higher odds of 48-hour major events.
Why the study?
The characteristics and outcomes of patients receiving bailout glycoprotein IIb/IIIa inhibitors for thrombotic complications of PCI in a large, contemporary trial were not fully described.
Does bailout use of glycoprotein IIb/IIIa inhibitors improve outcomes in patients with thrombotic complications of PCI?
Cohort (n=10,942)
Does bailout use of glycoprotein IIb/IIIa inhibitors improve outcomes in patients with thrombotic complications of PCI?
Bailout use of glycoprotein IIb/IIIa inhibitors for thrombotic complications during PCI is associated with very high risks of both ischemic and bleeding complications, highlighting the importance of preventing periprocedural complications.
Answers are grounded in this paper and cite their sources.
Bailout GP IIb/IIIa use signals high-risk PCI complications; leaves open causality versus confounding by indication.
AIMS: To describe the characteristics and outcomes of patients receiving bailout glycoprotein IIb/IIIa inhibitors (GPI) for thrombotic complications of percutaneous coronary intervention (PCI) in a large, contemporary trial. METHODS AND RESULTS: In the CHAMPION PHOENIX trial, the use of GPI was restricted to bailout for thrombotic complications. We describe the characteristics and outcomes of patients requiring bailout GPI compared to patients not receiving GPIs, with adjustment through propensity-score. A multivariable model was constructed to identify independent correlates associated with bailout GPI use. A total of 380 out of 10,942 patients received GPI (3.5%); GPI patients were younger, more frequently male, more likely to present with ST segment elevation myocardial infarction and less frequently treated with cangrelor. At 48 h, GPI patients experienced higher rates of the primary composite outcome of death, myocardial infarction, ischemia-driven revascularization, or stent thrombosis (ST) (19.2% vs 4.8%; adjusted OR: 5.65(4.08, 7.82), p < 0.0001) and a higher rate of GUSTO severe or moderate bleeding (2.6% vs 0.4% adjusted OR: 4.90 (1.98, 12.18), p = 0.0006) compared with non GPI patients. Independent correlates of GPI use were STEMI, use of unfractionated heparin, drug-eluting stents and longer procedure duration. CONCLUSIONS: In a large contemporary trial, patients receiving bailout GPI for thrombotic complications of PCI experienced very high risks of both ischemic and bleeding complications, suggesting that prevention of periprocedural complications rather than bailout GPI may be preferable. CLINICAL TRIAL REGISTRATION: http://www.clinicaltrials.gov identifier: NCT01156571.
No takes yet. Share an insight, caveat, or question.
Abtan et al. (2018) conducted a cohort in Thrombotic complications of percutaneous coronary intervention (n=10,942). Bailout glycoprotein IIb/IIIa inhibitors vs. Patients not receiving glycoprotein IIb/IIIa inhibitors was evaluated on Composite outcome of death, myocardial infarction, ischemia-driven revascularization, or stent thrombosis at 48 h (adjusted OR 5.65, 95% CI 4.08-7.82, p=< 0.0001). Bailout glycoprotein IIb/IIIa inhibitors for PCI complications were associated with higher 48-hour rates of death, MI, revascularization, or ST.
Synapse has enriched 10 related papers. Consider them for comparative context: